Low a-1 level is a significant predictor of recurrent CVD events
Boston Heart HDL Map Test
OVERVIEW OF THE HDL MAP
Standard HDL-C tests only measure the total amount of HDL-C contained by all HDL particles. Boston Heart’s exclusive HDL Map test measures the amount of apoA-I in the five most significant subpopulations, resulting in a deeper understanding of a patient’s CVD risk.
This exclusive method provides an accurate and consistent indication of reverse cholesterol transport by separating the larger, cardioprotective particles (α-1) most associated with decreased CVD risk from the smaller HDL particles which have been associated with increased risk.
The Boston Heart HDL Map® test assesses the five key HDL subpopulations linked to cardiovascular disease (CVD) risk through a unique gel electrophoresis technique. This method measures the amount of apoA-I protein in each of the five HDL subclasses, offering precise insights to identify patients at higher risk of CVD.
A low α-1 level is a critical indicator of recurrent CVD events. Studies have shown that low levels of α-1 HDL and high levels of pre ß-1 HDL are predictive of recurrent CVD events, particularly in men with low HDL-C (<40 mg/dL) and existing CVD. Notably, low α-1 HDL levels are the most significant predictor of CVD recurrence (p<0.001).
Treatment options include:
- Lifestyle modifications (if indicated)
- Low saturated fat intake (<7%)
- Low cholesterol intake (<200 mg/day)
- Low sugar intake
- Exercise for more than 30 minutes per day
- Smoking cessation
- Weight reduction (if indicated)
- Medications and their effects on HDL particles
Biomarkers in this category
5 biomarkers · optimal ranges shown
one of the key HDL subpopulations
one of the specific subpopulations of high-density lipoprotein (HDL) particles
small HDL particles
a distinct form of High-Density Lipoprotein (HDL)